ACELYRIN, INC.

ACELYRIN, INC. is a biopharmaceutical company headquartered in the United States with operations in the Los Angeles and San Francisco Bay areas. Founded in 2020, the company is strategically positioned in the Biopharma, Biotechnology, and Health Care industries, focusing on late-stage clinical development. Their commitment is articulated through their slogan, "We are a late-stage clinical biopharma company focused on providing life-changing new treatment options for patients,” indicating a patient-centric approach.

ACELYRIN has recently attracted significant attention from investors, with its latest investment being an acquisition investment on 01 February 2025 by Alumis. This move underscores investor confidence in their business model of identifying, acquiring, and accelerating promising product candidates. The company is instilling a corporate culture of Courageous Caring™, which emphasizes collaborative progress for addressing essential human health needs. This focus positions them as a pivotal player aiming to improve patients' life quality by alleviating disease burdens.